IDEAYA Biosciences Inc banner
Financial profile · Q3 FY2026

A pre-commercial oncology pipeline funded by lumpy partnerships and equity

IDEAYA’s pre-commercial model combines variable collaboration revenue with persistent research-led operating and cash losses. Physical capital needs are modest; development has been financed through partner payments and equity issuance.

What is developing

The prior-year revenue comparison was boosted by upfront Servier license revenue, whereas current collaboration revenue is recognized as development services are performed. Rising clinical costs and continuing operating cash use reinforce the existing partner-funded R&D model rather than indicating a product-sales run rate.

What matters next

Whether revenue from performed collaboration services keeps pace with clinical and commercial-preparation spending.

USD
Metric FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
(11.9m) (34.4m) (42m) (34.5m) (49.8m) (58.7m) (113m) (274.5m) (113.7m)
390k 890k 1.3m 1.4m 1.7m 2.1m 2.5m 2.4m 2.7m
140k 950k 2.2m 3.6m 8.2m 11.6m 18.5m 34.8m 46.1m
(2.3m) 4.2m 1.7m 4.2m 10.1m 10.9m 8.5m 13m 38m
0 0 0 0 0 0 0 — —
20k 100k 90k 80k 70k 60k 69k 25k 0
1.6m 1.7m (280k) 84.4m (17.8m) (41.6m) (13.2m) 11.5m 1.9m
(12.2m) (27.6m) (39.3m) 55.5m (55.8m) (87.2m) (115.2m) (247.6m) (71.1m)
(1.8m) (1.7m) (1.4m) (490k) (2.6m) (3.4m) (2.4m) (3.9m) (2.4m)
(7.2m) (61.5m) 3.6m (145.8m) (67m) (30m) (156.1m) (498.7m) 72.3m
(8.9m) (63.2m) 2.3m (146.2m) (69.7m) (33.4m) (158.5m) (502.6m) 70m
17.5m 105.5m 50.6m 108.8m 145.5m 97.2m 362.7m 677.6m 29.8m
0 (70k) 0 20m 0 0 — — —
17.5m 105.4m 50.6m 128.8m 145.5m 97.2m 362.7m 677.6m 29.8m
(3.7m) 14.6m 13.6m 38m 20m (23.4m) 89m (72.6m) 28.7m
(14m) (29.3m) (40.7m) 55m (58.4m) (90.6m) (117.6m) (251.4m) (73.5m)